The note establishing the equivalence of anti SARS-CoV-2 / COVID vaccines administered abroad has been released by the Ministry of Health. In particular, the following vaccines, administered by the competent foreign national health authorities, are recognized as equivalent to those carried out within the National Strategic Plan of vaccines for the prevention of SARS-CoV-2 infections: those for which the holder of the authorization when placed on the market is the same as in the European Union (the list is attached to the note); Covishield (Serum Institute of India), produced under license from AstraZeneca; R-CoVI (R-Pharm), manufactured under license from AstraZeneca; Covid-19 vaccine-recombinant (Fiocruz), manufactured under license from AstraZeneca.
Validity for the purpose of issuing the Green pass
According to the provisions of the provision that bears the signature of Giovanni Rezza, these vaccines are considered valid for the purpose of issuing the green Covid-19 certification in favor of Italian citizens (also residing abroad) to their cohabiting family members and to foreign citizens. who reside in Italy for work or study reasons, regardless of whether they are registered with the National Health Service or the Sasn (Health assistance for flight personnel), as well as all subjects registered in any capacity with the National Health Service who have been vaccinated at the abroad against SARS-CoV-2.
Loading…
In France, yes, partial to Chinese vaccines
Meanwhile, France partially opens to Chinese vaccines. People vaccinated abroad with Chinese vaccines will be eligible for the French health pass, provided they receive an additional dose of Pfizer / BioNTech or Moderna. These individuals, specifies the Paris government, will be able to obtain the health pass “7 days after the administration of a complementary dose of a messenger RNA vaccine”, namely Pfizer / BioNTech or Moderna, according to a decree published in the Official Gazette.
At present, there are four anti Covid vaccines authorized in the European Union by the European Medicines Agency and the EU Commission: Pfizer / BioNTech, Moderna, AstraZeneca and Janssen (Johnson & Johnson). Worldwide, WHO recognizes others: the Chinese Sinopharm and Sinovac vaccines, as well as equivalent versions of AstraZeneca produced outside the EU (such as the Indian Covishield vaccine). The Russian Sputnik IV vaccine, on the other hand, is not yet recognized by the European Union or the WHO. Until now, those vaccinated with Chinese vaccines could not get the French pass without redoing a full vaccination with a vaccine recognized by local authorities.
